Equities

Warby Parker Inc

WRBY:NYQ

Warby Parker Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)19.51
  • Today's Change0.20 / 1.04%
  • Shares traded2.53m
  • 1 Year change+79.48%
  • Beta--
Data delayed at least 15 minutes, as of Nov 09 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy3
Outperform6
Hold6
Sell0
Strong Sell0

Share price forecast in USD

The 13 analysts offering 12 month price targets for Warby Parker Inc have a median target of 22.00, with a high estimate of 23.00 and a low estimate of 16.00. The median estimate represents a 12.76% increase from the last price of 19.51.
High17.9%23.00
Med12.8%22.00
Low-18.0%16.00

Earnings history & estimates in USD

On Nov 07, 2024, Warby Parker Inc reported 3rd quarter 2024 earnings of 0.05 per share. This result was in line with the consensus of the 7 analysts following the company and exceeded last year's 3rd quarter results by 0.04.
The next earnings announcement is expected on Feb 26, 2025.
Average growth rate-32.39%
Warby Parker Inc reported annual 2023 earnings of 0.10 per share on Feb 28, 2024.
Average growth rate+81.25%
More ▼

Revenue history & estimates in USD

Warby Parker Inc had 3rd quarter 2024 revenues of 192.45m. This bettered the 190.12m consensus of the 13 analysts covering the company. This was 11.91% above the prior year's 3rd quarter results.
Average growth rate+3.80%
Warby Parker Inc had revenues for the full year 2023 of 669.77m. This was 11.98% above the prior year's results.
Average growth rate+11.29%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.